Targeted drug delivery

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Potential, Visual acuity, Patient, Research, American Medical Association, Targeted drug delivery, Conference, American Academy of Ophthalmology, R, Diabetes, Diabetic retinopathy, Webcast, Literature, American Academy, Administration, DME, G&A, Research and development, Physician, Paratriathlon, Retina, Drug delivery, Pharming, Eye, Intravitreal injection, BioCryst Pharmaceuticals, SCS, Edema, AAO, Melanoma, AURA, Solubility, Partnership, AMD, Clearside, Bausch & Lomb, OASIS, Axitinib, Plasma, Clinical trial, CLS, CPT, Conference call, UME, Injection, HIV disease progression rates, Pharmaceutical industry, Nursing, Video game

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
  • Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

Retrieved on: 
Monday, September 25, 2023
Molecule, University, D, Kidney, Household & Commercial Products Association, Cancer, Hope, Research, University of Science and Technology of China, Patient, File, School, Quality control, Exosome, FDA, Therapy, IND, NMPA, Targeted drug delivery, Autoimmunity, Medicine, Vaccine, Southeast University

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.

Key Points: 
  • SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.
  • The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, process development, novel system design, and ideas on innovation.
  • Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing".
  • In 2021, Kexing Biopharm partnered with Southeast University to establish the "Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology".

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

Retrieved on: 
Monday, September 25, 2023
Molecule, University, D, Kidney, Household & Commercial Products Association, Cancer, Hope, Research, University of Science and Technology of China, Patient, File, School, Quality control, Exosome, FDA, Therapy, IND, NMPA, Targeted drug delivery, Autoimmunity, Medicine, Vaccine, Southeast University

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.

Key Points: 
  • SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.
  • The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, process development, novel system design, and ideas on innovation.
  • Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing".
  • In 2021, Kexing Biopharm partnered with Southeast University to establish the "Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology".

Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

Retrieved on: 
Thursday, September 7, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, DNA, Travel, EPHS, Macrophage, FASL, Cancer, Targeted drug delivery, Inflammation, Biomedical engineering, COYA, Plasma, Biomedicine, Coya, Engineering, Apoptosis, Epitope, Mouse, CMU, Exosome, Therapy, Pharmaceutical industry, Vaccine, Regulatory T cell

It was also demonstrated that CTLA-4-Treg exosomes exhibited far better cell uptake then non-modified Treg EVs in representative immune cells, macrophages (J7774 murine cell line) and T-cells (human Jurket cell line).

Key Points: 
  • It was also demonstrated that CTLA-4-Treg exosomes exhibited far better cell uptake then non-modified Treg EVs in representative immune cells, macrophages (J7774 murine cell line) and T-cells (human Jurket cell line).
  • Previously, using the same technology, CMU demonstrated applications in Oncology by engineering mesenchymal derived exosomes with an immunomodulatory apoptotic inducing protein, Fas Ligand (FAS-L).
  • Treg-derived exosomes share many of the properties of the parent Treg cells making them able to modulate physiological and pathophysiological processes.
  • Delivering EPHs to sites of inflammation or epitopes that drive specific diseases, while delivering customized loads, enables the next generation of selectively targeted and potent Treg-derived exosomes.

CENTER FOR PAIN MANAGEMENT WELCOMES DR. JOSHUA WELLINGTON, MD.

Retrieved on: 
Friday, September 1, 2023
Spaulding Rehabilitation Hospital, Boston Children's Hospital, Intrathecal pump, Piriformis syndrome, Beth Israel Deaconess Medical Center, Neck pain, Arthralgia, Interventional pain management, Arthritis, Medical college, Therapy, Twilight anesthesia, ITP, Cancer, North American Neuromodulation Society, American Academy, CRPS, Medicine, MS, Harvard Medical School, Public key certificate, Back pain, Rehabilitation, Medical director, Patient, Physician, Practitioner, Physical medicine and rehabilitation, Fibromyalgia, Hospital, Health, NANS, Chronic pain, Headache, Society, Targeted drug delivery, Injury, Nursing, Dentistry, Pain management, MD

INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.

Key Points: 
  • INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.
  • He will be joining Center for Pain Management to lead the Targeted Drug Delivery program, which will expand patient access to quality care for Intrathecal Pump (ITP) implants.
  • Center for Pain Management, supported by American Pain Consortium, proudly serves Indiana with 7 clinics and 4 Ambulatory Surgery Centers statewide and has been treating a wide range of acute and chronic pain conditions since 1993.
  • The physicians specialize in back pain, neck pain, headache, and joint pain resulting from injuries, arthritis, cancer, fibromyalgia, failed back surgery, Complex Regional Pain Syndromes (CRPS), and other disorders.

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

Retrieved on: 
Wednesday, March 30, 2022
Company, Private Securities Litigation Reform Act, Agitation, NASDAQ, Autism, Ben-Gurion University of the Negev, Chemical engineering, Central nervous system, IND, THC, Research, SEC, Risk, Coronavirus Scientific Advisory Board (Turkey), Status epilepticus, Medicine, Targeted drug delivery, Pain, Peripheral nervous system, Negev, Nanotechnology, Safety, Chronic pain, Intention, U.S. Securities and Exchange Commission, CBD, TEL, CB2, GLOBE, Physician, SAB, Tourette syndrome, Annual report, Alzheimer's disease, Technology, Cannabinoid, MIT, Pharmaceutical industry, Technion – Israel Institute of Technology

TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonist’s biological effect and extend effect duration.

Key Points: 
  • As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain.
  • Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonists biological effect and extend effect duration.
  • The Company previously achieved positive results in a series of pre-clinical trials in which the efficacy and safety of SCI-160 was demonstrated in both acute and chronic pain.
  • Prof. Schroeder received three degrees in Chemical Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took place at MIT.

Pentec Health welcomes Eric C. Mollman as Chief Financial Officer

Retrieved on: 
Monday, March 21, 2022
Company, Health, BA, Organization, Wellspring Capital Management, Dialysis, Sale, EVP, Investment, University of Chicago Booth School of Business, Growth, Help, Business, Ownership, M&A, Cerberus Capital Management, Defense Finance and Accounting Service, Harvard College, Home, CEO, Targeted drug delivery, Board of directors, Industry, Safety, Acquisition, Visiting Nurse Service of New York, Accounting, University of Chicago, University, Patient, Partnership, Management, Wellspring, Economics

PHILADELPHIA, March 21, 2022 /PRNewswire-PRWeb/ -- Pentec Health Inc., a nationwide leader in providing patient-specific compounded sterile medications and complex in-home clinical services, welcomes Eric C. Mollman, Chief Financial Officer.

Key Points: 
  • PHILADELPHIA, March 21, 2022 /PRNewswire-PRWeb/ -- Pentec Health Inc., a nationwide leader in providing patient-specific compounded sterile medications and complex in-home clinical services, welcomes Eric C. Mollman, Chief Financial Officer.
  • Eric brings over 35 years of experience in finance to Pentec, and over 15 years of experience as a Chief Financial Officer in the healthcare industry.
  • Eric was most recently Chief Financial Officer at Help at Home, a home care service company.
  • As Chief Financial Officer Eric will have primary oversight of the Company's accounting and financial operations.

Medtronic announces schedule for presentations at the 2022 North American Neuromodulation Society Meeting

Retrieved on: 
Wednesday, January 12, 2022
Targeted drug delivery, LinkedIn, NYSE, Patient, Chronic pain, Perception, Lucia v. Securities and Exchange Commission, TDD, Stimulation, Tradition, Multiplexing, Technology, STN, Safety, NMP, Effect, DTM, Hyperreflexia, RCT, PSR, Parkinsonism, Solution, Neuropathic pain, Health, Pain, Randomized controlled trial, Longitudinal study, Neck pain, SCS, Sense, Method, Feasibility study, Poster, Functional, Twitter, Security (finance), Medical device, Pharmaceutical industry, Poultry, Trapping, Vaccine, Medtronic

DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida. Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations. The company will also welcome guests to booth #404 featuring an innovation suite and opportunities to learn from Medtronic scientists and engineers about the new Vanta™ recharge-free neurostimulator, as well as a new modified energy variation of Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation known as DTM™ SCS endurance therapy. Medtronic will also showcase its targeted drug delivery options for patients with chronic pain.

Key Points: 
  • DUBLIN, Jan. 12, 2022 /PRNewswire/ --Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida.
  • Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations.
  • The following poster and oral scientific data presentations reflect evidence from Medtronic-sponsored research and collaborations with external partners.
  • For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

New data presented at OARSI 2021 Virtual World Congress by AKL Research and Development advances understanding of biological effects of its investigational osteoarthritis drug APPA to protect against joint damage

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Skeletal disorders, Medical specialties, Clinical medicine, Arthritis, Osteoarthritis, Targeted drug delivery, Analgesic

Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.

Key Points: 
  • Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.
  • This builds on earlier research looking at neutrophils which showed that APPA may have significant anti-inflammatory potential.
  • "\nRegulatory guidance from the FDA states that any new OA drug targeting disease modification must also demonstrate symptomatic pain relief.
  • For more information, visit: https://www.aklrd.com/\n[3]FOOD AND DRUG ADMINISTRATION: Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment Guidance for Industry.

New data presented at OARSI 2021 Virtual World Congress by AKL Research and Development advances understanding of biological effects of its investigational osteoarthritis drug APPA to protect against joint damage

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Skeletal disorders, Medical specialties, Clinical medicine, Arthritis, Osteoarthritis, Targeted drug delivery, Analgesic

Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.

Key Points: 
  • Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.
  • This builds on earlier research looking at neutrophils which showed that APPA may have significant anti-inflammatory potential.
  • "\nRegulatory guidance from the FDA states that any new OA drug targeting disease modification must also demonstrate symptomatic pain relief.
  • For more information, visit: https://www.aklrd.com/\n[3]FOOD AND DRUG ADMINISTRATION: Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment Guidance for Industry.